We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
Rocket Pharmaceuticals
RCKT
$382M
| $853K | ﹤0.01% |
37,493
+670
| +2% | +$11.2K |
|
|
CRC
2152
DELISTED
California Resources Corporation
CRC
| $853K | ﹤0.01% |
94,439
+8,337
| +10% | +$67.5K |
|
|
YMAB
2153
DELISTED
Y-mAbs Therapeutics
YMAB
| $851K | ﹤0.01% |
27,222
+5,169
| +23% | +$153K |
|
|
KDMN
2154
DELISTED
Kadmon Holdings, Inc.
KDMN
| $851K | ﹤0.01% |
187,852
+26,397
| +16% | +$96.6K |
|
2155
BrightView Holdings
BV
$988M
| $850K | ﹤0.01% |
50,370
+665
| +1% | +$11.6K |
|
2156
Ducommun
DCO
$2.89B
| $849K | ﹤0.01% |
16,809
+105
| +0.6% | +$4.83K |
|
|
VCRA
2157
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $848K | ﹤0.01% |
40,863
+456
| +1% | +$10K |
|
|
FBMS
2158
DELISTED
The First Bancshares, Inc.
FBMS
| $844K | ﹤0.01% |
23,766
+390
| +2% | +$12.9K |
|
|
ADVM
2159
DELISTED
Adverum Biotechnologies
ADVM
| $843K | ﹤0.01% |
7,322
+68
| +0.9% | +$5.99K |
|
|
ANAT
2160
DELISTED
American National Group, Inc. Common Stock
ANAT
| $836K | ﹤0.01% |
7,104
+504
| +8% | +$59.6K |
|
|
UMH
2161
UMH Properties
UMH
$1.29B
| $835K | ﹤0.01% |
53,096
+3,324
| +7% | +$50.1K |
|
2162
Smith & Wesson
SWBI
$658M
| $829K | ﹤0.01% |
116,250
-1,359
| -1% | -$8.28K |
|
2163
Select Water Solutions
WTTR
$2.77B
| $827K | ﹤0.01% |
89,155
+1,115
| +1% | +$9K |
|
2164
Community Health Systems
CYH
$416M
| $825K | ﹤0.01% |
284,615
+19,662
| +7% | +$68.1K |
|
|
CONN
2165
DELISTED
Conn's Inc.
CONN
| $819K | ﹤0.01% |
66,078
+1,976
| +3% | +$41.4K |
|
|
TPC
2166
Tutor Perini Cor
TPC
$4.45B
| $817K | ﹤0.01% |
63,552
+637
| +1% | +$9.82K |
|
|
WMC
2167
DELISTED
Western Asset Mortgage Capital Corporation
WMC
| $814K | ﹤0.01% |
7,878
+175
| +2% | +$17.7K |
|
|
CPLG
2168
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $813K | ﹤0.01% |
76,106
+4,010
| +6% | +$40.5K |
|
2169
The RMR Group
RMR
$324M
| $812K | ﹤0.01% |
17,785
+350
| +2% | +$16.2K |
|
|
EXTN
2170
DELISTED
Exterran Corporation
EXTN
| $811K | ﹤0.01% |
103,595
+1,024
| +1% | +$9.5K |
|
2171
Arrow Financial
AROW
$670M
| $809K | ﹤0.01% |
24,080
+1,323
| +6% | +$41.6K |
|
|
PR
2172
Permian Resources
PR
$16.6B
| $809K | ﹤0.01% |
175,083
+19,740
| +13% | +$72.2K |
|
2173
Axogen
AXGN
$2.43B
| $807K | ﹤0.01% |
45,095
+252
| +0.6% | +$3.72K |
|
|
OLP
2174
One Liberty Properties
OLP
$520M
| $807K | ﹤0.01% |
29,666
+1,145
| +4% | +$31.5K |
|
2175
Viking Therapeutics
VKTX
$3.91B
| $807K | ﹤0.01% |
100,608
+986
| +1% | +$7.19K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.